Skip to main navigation menu Skip to main content Skip to site footer
JASBB Baner text

No. ONLINE FIRST

Articles

Resistance of Pseudomonas aeruginosa strains to Rivanol

DOI: https://doi.org/10.24326/jasbb.2026.5586
Submitted: August 18, 2025
Published: 29.04.2026

Abstract

The aim of the study was to determine the sensitivity of two strains of Pseudomonas aeruginosa to Rivanol 0.1% (ethacridine). The tests were carried out using the macrodilution method in Brain Heart Infusion (BHI) broth in the concentration range from 1 : 512 to 1 : 1, using an inoculum with a density of 0.5 McFarland. The values of the minimum inhibitory concentration (MIC)  and the minimum bactericidal concentration (MBC) were assessed. It was found that both strains showed bacterial growth in most of the tested concentrations, and complete inhibition of  bacterial growth and bactericidal effect were noted only at the highest concentration used (1 : 1). These results indicate a high resistance of the tested P. aeruginosa strains to Rivanol, which may limit its use in the therapy of infections caused by this species. Further research on more effective antibacterial compounds and strategies supporting the therapy of infections caused by multidrug-resistant strains seems to be necessary.

References

  1. Akiola Sanya D.R., Onésime D., Vizzarro G. et al., 2023. Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections. BMC Microbiol. 23, 86. https://doi.org/10.1186/s12866-023-02832-x
  2. Egorova D.A., Solovyev A.I., Polyakov N.B. et al., 2022. Biofilm matrix proteome of clinical strain of Pseudomonas aeruginosa isolated from bronchoalveolar lavage of patient in intensive care unit. Microb. Pathog. 170, 105714. https://doi.org/10.1016/j.micpath.2022.105714
  3. Namaki M., Habibzadeh S., Vaez H. et al., 2022. Prevalence of resistance genes to biocides in antibiotic-resistant Pseudomonas aeruginosa clinical isolates. Mol. Biol. Rep. 49, 2149–2155. https://doi.org/10.1007/s11033-021-07032-2
  4. Melville P., Benites N., Sinhorini I. et al., 2003. Susceptibility and features of the ultrastructure of Prototheca zopfii following exposure to copper sulphate, silver nitrate and chlorexidine. Mycopathologia 156, 1–7. https://doi.org/10.1023/A:1021313118632
  5. Pang Z., Raudonis R., Glick B.R. et al., 2019. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol. Adv. 37(1), 177–192. https://doi.org/10.1016/j.biotechadv.2018.11.013
  6. Qin S., Xiao W., Zhou C. et al., 2022. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct. Target Ther. 7, 199. https://doi.org/10.1038/s41392-022-01056-1
  7. Qais F.A., Altaf M., Ahmad I., 2023. Management of virulence in Pseudomonas aeruginosa and Serratia marcescens using environmentally‑friendly titanium dioxide nanoparticles. RSC Adv. 13, 35841–35852. https://doi.org/10.1039/D3RA06536G
  8. Jabri T., Khan N.A., Makhlouf Z. et al., 2023. Antibacterial properties of ethacridine lactate and sulfmethoxazole loaded functionalized graphene oxide nanocomposites. Antibiotics 12(4), 755. https://doi.org/10.3390/antibiotics12040755
  9. Targońska-Karasek M., Polkowska I., Krukowski H., 2025. Is Pseudomonas aeruginosa a possible aetiological agent of periodontitis in dogs? J. Vet. Res. 69(1), 35–40. https://doi.org/10.2478/jvetres-2025-0006
  10. WHO, 2017. WHO publishes list of bacteria for which new antibiotics are urgently needed. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed

Downloads

Download data is not yet available.

Most read articles by the same author(s)

<< < 1 2